Fundraising Fox

DCVC Bio β€” Full Portfolio

25 tracked investments Β· listed companies and verified rows first

Fervo Energyfervoenergy.cominNASDAQ: FRVO

Fervo Energy develops next-generation geothermal technology using advanced drilling and sensing techniques to unlock carbon-free, 24/7 power generation in previously uneconomic locations.

CleantechClimate TechEnergyHouston, US

Tim Latimer(Founder & CEO)inJack Norbeck(Founder)in

BoardDavid Thomas Danielson(Director)inNicholas Walrod(Director)Ion Yadigaroglu(Director)

Co-investorsB Capital GroupB4 CapitalBaruch Future VenturesBeast VenturesBreakthrough Energy VenturesCarbon+13 more

Umoja Biopharma, Inc.umoja-biopharma.comin𝕏Jun 2021βœ“ verified

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.

BiotechHealthtechSeattle, US

Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)

BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)

Board seatJohn HamerΒ· per SEC Form D

Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)

Alchemab Therapeuticsalchemab.cominπ•βœ“ verified

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

Jane Osbourn(Chief Executive Officer)

Co-investorsSV Health InvestorsRA CapitalDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.DCVC (Data Collective)

Fablefabletherapeutics.comβœ“ verified

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsMPM BioImpactLilly Asia VenturesVersant VenturesDCVC (Data Collective)

Avicenna Biosciencesin𝕏Oct 2025

BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.

BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US

Pieter Burger(Executive Officer, Director)Thomas Kaiser(Executive Officer, Director)

BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)

Board seatJohn HamerΒ· per SEC Form D

ELO LIFE SYSTEMS, INC.Jan 2024SEC filingmedium confidence

Durham, US

Michele Fite(Executive Officer)Matthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)Paul Boyer(Executive Officer)Fayaz Khazi(Executive Officer, Director)Kartik Dharmadhikari(Director)

Board seatKiersten SteadΒ· per SEC Form D Β· $25M raise Β· filed Jan 2024

Empirico Inc.Mar 2023SEC filingmedium confidence

San Diego, US

Board seatJohn HamerΒ· per SEC Form D Β· $55.2M raise Β· filed Mar 2023

Epsilon Holdings, Inc.Dec 2021SEC filingmedium confidence

Durham, US

Board seatKiersten SteadΒ· per SEC Form D Β· $24.5M raise Β· filed Dec 2021

MycoWorksmycoworks.comin𝕏Jun 2023

MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.

BiotechCircular EconomyNew MaterialsEmeryville, US

Philip Ross(Director)Michael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)

BoardThomas Grotkjaer(Director)

Board seatKiersten SteadΒ· per SEC Form D

Co-investorsDCVC (Data Collective)Hemisphere Ventures LLCWireframe Ventures8VCAgFunderHumboldt+3 more

Unlearnunlearn.aiin𝕏Apr 2022

Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.

AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US

Charles Fisher(Founder & CEO)inAaron Smith(Founder)

Board seatJohn HamerΒ· per SEC Form D

Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Eisai Innovation, Inc.Flucas Ventures+5 more

AgZenagzen.comin𝕏

AgZen develops real-time monitoring technology for crop spraying, analyzing droplet behavior to help growers and agricultural equipment manufacturers optimize application efficiency.

AgTechAI & Machine LearningFintechHardwareImpact & Social GoodMedia & Entertainment

Vishnu Jayaprakash(Founder)inKripa VaranasiMaher Damak

Co-investorsAstanor VenturesMaterial ImpactDCVC (Data Collective)Syngenta Group Ventures

CH4 Globalch4global.comin

CH4 Global develops greenhouse gas mitigation solutions centered on Asparagopsis seaweed, producing feed supplements that reduce enteric methane emissions from cattle for the livestock and agriculture industries.

AgTechCleantechClimate TechFoodTech

Steve Meller(CEO, President & Co-Founder)in

Co-investorsCleveland AvenueDCVC (Data Collective)AgFunder

Creyon Biocreyonbio.comin𝕏

Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.

AI & Machine LearningBiotechDeep Tech

Co-investorsBioBritDCVC (Data Collective)Tenmile

Dcvcdcvc.com
Frontier Medicinesfrontiermeds.comin𝕏Aug 2025 Β· $80M

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.

AI & Machine LearningBiotechSouth San Francisco, US

Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)

Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactRA CapitalDeerfield Management Company

Greaterlongislandgreaterlongisland.com
Grove Biopharmagrovebiopharma.comin

Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions.

BiotechDeep TechChicago, US

Geoffrey Duyk(CEO)

Co-investorsDCVC (Data Collective)InVivium CapitalPortal Innovations

nChroma Bionchromabio.comin𝕏

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD

Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM Ventures+1 more

Newleos Therapeuticsnewleostherapeutics.cominFeb 2025 Β· $93.5M

BiotechBoston, US

David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in

BoardChristoph Westphal(Director)Ming Cheah(Director)Raymond Camahort(Director)

Co-investorsDCVC (Data Collective)Longwood FundNovo Holdings

Newyorkernewyorker.com
Nilonilo.worldinOct 2025 Β· $101M

NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.

Circular EconomyCleantechNew Materials

Co-investorsArc AngelsIcehouse VenturesLux CapitalThe Column Group

Nilo TherapeuticsJul 2024

BiotechNew York, US

Jeff Goater(Executive Officer, Director)

BoardTim Kutzkey(Executive Officer, Director, Promoter)

Co-investorsDCVC (Data Collective)Lux CapitalThe Column Group

Nilo Therapeuticsnilotx.comOct 2025

Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.

BiotechDeep TechHealthtech

Co-investorsThe Column GroupLux Capital

Sidewinder Therapeutics

Advancing precision bispecific antibody-drug conjugates to treat cancer

Co-investorsDCVC (Data Collective)Frazier Life SciencesNovartis Venture Fund

Syntaxsyntax-bio.comin

Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.

BiotechDeep TechMedical Devices

Ryan Clarke(Founder)in

Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Draper AssociatesIllumina VenturesPortal Innovations

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.